Brief: Sinomab Bioscience Says Phase III Clinical Study Of Sm03 In Rheumatoid Arthritis Meets Primary Endpoint
26/04/2023 15:27
April 26 (Reuters) - SinoMab BioScience Ltd 3681.HK :
* PHASE III CLINICAL STUDY OF SM03 (SUCIRASLIMAB) IN
RHEUMATOID
ARTHRITIS MEETS PRIMARY ENDPOINT
Further company coverage: 3681.HK
Recent news on Sinomab Bioscience
See all newsBrief: Sinomab Bioscience Posts HY Loss Of RMB127.4 Million
Brief: Sinomab Bioscience Says Fang Liang Resigns As Executive Director
Brief: Sinomab Bioscience Announces Major Deal For Disposal Of Suzhou Property And Facility For RMB280 MLN
Brief: SinoMab Bioscience Appoints Fang Liang As Executive Director
Brief: Hainan Haiyao Plans To Unload Stake In Sinomab Bioscience